Peptides and pregnancy preparation — what to discontinue, what may help preconception

This is the preconception window, and it doesn't get nearly the clinical attention it deserves. The focus of reproductive medicine tends to be on the moment of trying — ovulation timing, cycle tracking, the fertility workup when things don't happen quickly. But the three to six months before you start trying are when the biological foundations that support conception are actually being built. Egg quality — which is one of the most significant variables in both conception and early pregnancy outcome — reflects the maturation conditions of the preceding months, not the moment of ovulation. The oocyte that you ovulate in month three of trying was developing during month one of preparing. What you do in that earlier window matters.

The first and most important framework is what to discontinue. Not as caution theater, but because the reasons are specific and meaningful.

GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide — require washout before conception attempts. Current guidance, which continues to evolve and should be confirmed with your prescribing provider, generally recommends discontinuing semaglutide at least two months before planned conception; longer washouts are sometimes recommended given the extended half-life of the compound. The reason is not a documented human teratogen signal — the data in humans is limited — but the preclinical data shows fetal harm at clinically relevant doses, and the risk-benefit calculation during pregnancy clearly does not support GLP-1 agonist continuation. The washout window matters because residual drug exposure during early embryonic development — before you know you're pregnant — is the risk to avoid. Discuss the specific timing with your prescribing provider because guidance in this area is genuinely active; what was standard guidance a year ago has continued to be refined.

Growth hormone-axis peptides — sermorelin, ipamorelin, CJC-1295, tesamorelin — should be discontinued before attempting conception. Growth hormone physiology is deeply implicated in embryonic and fetal development; this is not a class of compounds to carry into the preconception period or beyond. The research safety data in human pregnancy is absent, and the precautionary case for discontinuation is clear. Allow adequate clearance time, and discuss timing with your provider.

BPC-157 and TB-500 should be discontinued during the preconception period. Both have angiogenic activity — they promote new blood vessel formation, which is part of what makes them interesting for tissue repair in research contexts. That same angiogenic activity is a reason for caution in a context where placental vascularization is being established. There are no human pregnancy safety data for either compound. The mechanism-based concern is real enough that the appropriate posture is discontinuation, not continuation.

Melanocortin peptides — PT-141 and related compounds — should be discontinued. Research peptides without established safety profiles in human pregnancy should be discontinued. As a general principle, any compound that is not definitively established as safe in pregnancy — and the list of such compounds is short and specific — belongs on the discontinue list when you are actively trying to conceive.

What remains after discontinuing the wellness peptide protocols is the actual preconception optimization work, which is substantive on its own and deserves the same seriousness as the compounds you've been taking.

Body weight is one of the most significant modifiable fertility variables, and it operates in both directions. Overweight, as defined by clinical fertility metrics, is associated with ovulatory dysfunction — excess adipose tissue drives peripheral aromatization of androgens to estrogens, disrupting the precise hormonal signaling the hypothalamic-pituitary-ovarian axis requires. This is one of the mechanisms through which insulin resistance, which frequently accompanies overweight, impairs fertility. Underweight creates a different but comparably significant problem: the hypothalamus is sensitive to energy availability, and when energy stores fall below a threshold, the pulsatile GnRH release that drives the HPO axis can be suppressed. Hypothalamic amenorrhea — the loss of regular ovulation in response to insufficient energy availability, often combined with high exercise load — is a specific diagnosis with a specific trajectory of recovery. The weight optimization conversation in preconception is about where you are on this spectrum, not about an aesthetic target.

Glucose management matters enormously in the preconception period and gets insufficient attention outside of formal diabetes care. Insulin resistance impairs fertility through multiple mechanisms: elevated insulin drives ovarian androgen production, contributing to conditions like PCOS; disrupted glucose metabolism affects oocyte quality at a cellular level; and the inflammatory state that accompanies chronic insulin resistance creates an unfavorable environment for implantation and early embryonic development. For women who were using GLP-1 agonists for weight or glucose management, the preconception period involves managing glucose through non-pharmacological means — dietary composition, meal timing, exercise — with the support of your prescribing provider. This is a meaningful clinical transition and not one to navigate alone.

Nutritional adequacy in the preconception period is not optional. Folate is the canonical example: neural tube development occurs in the first twenty-eight days of embryonic life, often before a positive pregnancy test. The recommendation to begin folate supplementation before conception rather than after a positive test exists precisely because the critical window arrives before confirmation. Active folate (5-MTHF) is often recommended over folic acid for women with MTHFR variants that impair folic acid conversion, though this is a conversation for your provider to individualize. B12 matters particularly for vegetarian and vegan women. Vitamin D deficiency is common in reproductive-age women and has documented associations with fertility outcomes, early pregnancy loss risk, and pregnancy complications. Omega-3 fatty acids — specifically DHA — are important for fetal neurodevelopment and for the inflammatory environment of early pregnancy. Iron stores should be checked, because iron-deficiency anemia depleted before pregnancy becomes more depleted during it. Getting these foundations right before conception is easier than correcting deficiencies during it.

Thyroid optimization is a preconception priority that often surfaces only when there's a known thyroid condition. But subclinical hypothyroidism — TSH elevated but below the clinical diagnostic threshold for treatment in the general population — is commonly treated to lower targets in reproductive contexts. Most reproductive endocrinologists aim for a TSH below 2.5 mIU/L in women trying to conceive, rather than the standard upper limit of 4-5 mIU/L used in general medicine. If your thyroid hasn't been checked recently, preconception is the right time. If you have Hashimoto's thyroiditis — which is common and often undiagnosed — monitoring thyroid antibodies and TSH in the preconception period is important, because the autoimmune thyroid disease context changes the fertility and early pregnancy picture significantly.

The fertility-specific peptide and pharmacological landscape in preconception is a narrower, more clinically supervised territory than the wellness peptide space. Human chorionic gonadotropin (HCG) is an FDA-approved medication used in specific clinical contexts including ovulation induction, under reproductive endocrinology supervision. Gonadorelin — a GnRH analogue — has been used in the context of hypothalamic amenorrhea to stimulate pulsatile gonadotropin release where the hypothalamus isn't generating adequate signal. Kisspeptin is an area of active research interest for its role in HPO axis regulation and fertility support, with human clinical studies exploring its potential in specific fertility contexts. These are not over-the-counter or self-directed interventions. They are specialized tools within fertility medicine, used with appropriate diagnostic context and clinical monitoring.

The male partner dimension of preconception preparation is consistently underweighted. Sperm quality — morphology, motility, count, DNA fragmentation — contributes to both the likelihood of conception and the quality of the resulting embryo. Sperm production reflects conditions over the preceding ninety days, the approximate duration of spermatogenesis. This means the lifestyle and environmental exposures of the three months before actively trying to conceive are the ones that matter most for sperm quality. Alcohol consumption impairs both testosterone and sperm production. Smoking has well-documented negative effects on sperm DNA integrity. Heat exposure — hot tubs, laptop use on the lap, tight clothing — impairs sperm production, which is why the testes are external: optimal spermatogenesis requires temperatures slightly below core body temperature. Obesity in men is associated with lower testosterone, elevated estrogen, and impaired sperm quality through mechanisms related to adipose aromatization. Varicocele, which is an enlarged vein in the scrotum, is present in a significant minority of men and is the most common surgically correctable cause of male infertility. A basic semen analysis is relatively cheap and informative; there is no good argument for not doing it when a couple is planning conception.

The mental health dimension of preconception doesn't get adequate clinical attention either. The preconception period can be laden with anxiety — about the process, about outcomes, about the timing. Stress does affect fertility — specifically, the HPA axis and the HPO axis share significant regulatory overlap, and sustained cortisol elevation can suppress GnRH pulsatility. This is not a reason to dismiss fertility anxiety as a character failing that requires straightening out. It is a reason to take stress management as seriously as the nutritional and pharmacological preparations, and to build support structures before the process becomes more demanding.

The honest framing is that the preconception period is reproductive endocrinology territory, not wellness territory, and the distinction matters. Wellness optimization can support the foundations — metabolic health, nutritional status, body composition, stress management. But decisions about what to discontinue and when, what thyroid targets to aim for, whether a fertility workup is warranted, and how to manage the transition off medications that were serving a purpose require clinical evaluation by a provider with appropriate expertise. A reproductive endocrinologist, an OB-GYN with fertility experience, or an internist or NP who specializes in reproductive health are the right people to be having these conversations with.

The window before you start trying is arguably the highest-leverage moment in the entire preconception-to-pregnancy arc. The biological work of early embryonic development begins before you know it has begun. The oocyte quality that determines that development reflects months of prior conditions. The thyroid function that either supports or disrupts early placentation is whatever it is before conception, and finding out at eight weeks that it wasn't optimal means you've already been operating in that context for eight weeks. The three to six months before trying to conceive are not waiting time. They are preparation time. The distinction is not semantic. What you do in that window is part of what the pregnancy begins with.